



## Appendix 2

**Table 2. Case reports and case series of steroid-refractory ICI-induced pneumonitis treated with infliximab**

Author (Year)	Study design	Cancer type; (ICI)	Number of patients	Grade of pneumonitis	Steroid refractory	Prior additional treatment	Infliximab dose and number of infusions	Response to infliximab treatment
<b>Case reports and single cases from case series</b>								
Vera et al. (2025) <sup>19</sup>	Case report	Hepatocellular carcinoma; (atezolizumab)	1	4	Yes	IVIg (1 g/kg) for 3 days	Dose: 5 mg/kg No. infusions: 2	No response
Bischin et al. (2025) <sup>14</sup>	Case report	Urothelial carcinoma (pembrolizumab)	1	4	Yes	NR	Dose 1: 5 mg/kg Dose 2: 10 mg/kg No. infusions: 2	Complete response
Adams et al. (2025) <sup>20</sup>	Case series	Not specified	1	NR	Yes	NR	NR	Complete response
Varathalajaru et al. (2025) <sup>12</sup>	Case report	Breast cancer and mesothelioma (nivolumab and ipilimumab)	1	NR	Yes	NR	NR	Partial response
Torres et al. (2024) <sup>18</sup>	Case report	Bladder cancer (nivolumab)	1	NR	Yes	NR	Dose: 5 mg/kg No. infusions: 1 + MMF	Improved with no adverse events
Sharif et al. (2024) <sup>24</sup>	Case report	NSCLC (durvalumab)	1	4	Yes	NR	Dose: NR No. infusions: 2	Gradual improvement

Author (Year)	Study design	Cancer type; (ICI)	Number of patients	Grade of pneumonitis	Steroid refractory	Prior additional treatment	Infliximab dose and number of infusions	Response to infliximab treatment
<b>Case reports and single cases from case series</b>								
Pan et al. (2023) <sup>21</sup>	Case report	NSCLC (camrelizumab)	1	4	Yes	NR	Dose: 500 mg No. infusions: 1	Improved, continued ICI treatment with stable disease
Gökmen et al. (2023) <sup>22</sup>	Case series	Not specified	1	NR	Yes	NR	NR	Improvement
Buntak et al. (2023) <sup>15</sup>	Case report	Oesophageal cancer (nivolumab)	1	NR	Yes	tocilizumab (8 mg/kg)	Dose: 5 mg/kg No. infusions: 1 + IVIG (0.4 g/kg)	Transient improvement
Allen et al. (2023) <sup>25</sup>	Case series	NSCLC ICI not specified	1	4	Yes	NR	Dose: NR No. infusions: NR + cyclophosphamide	No response
Segui et al. (2022) <sup>28</sup>	Case series	Bladder cancer (atezolizumab)	1	NR	Yes	NR	NR	No response
Kunimasa et al. (2022) <sup>11</sup>	Case report	NSCLC (nivolumab and ipilimumab)	1	4	Yes	tocilizumab (8 mg/kg)	Dose: 5 mg/kg No. infusions: 1	Clinical improvement
Shah et al. (2022) <sup>17</sup>	Case report	Hepatocellular carcinoma (atezolizumab)	1	NR	Yes	NR	Dose: 5 mg/kg No. infusions: 1	Clinical improvement
Arana-Riberio et al. (2021) <sup>13</sup>	Case report	NSCLC (pembrolizumab)	1	NR	Yes	NR	Dose: 5 mg/kg No. infusions: 1	No response

Author (Year)	Study design	Cancer type; (ICI)	Number of patients	Grade of pneumonitis	Steroid refractory	Prior additional treatment	Infliximab dose and number of infusions	Response to infliximab treatment
<b>Case reports and single cases from case series</b>								
Nagasunder et al. (2020) <sup>26</sup>	Case report	Melanoma (pembrolizumab)	1	3	Yes	NR	NR	No response
Burdett et al. (2020) <sup>27</sup>	Case series	Not specified	1	NR	Yes	NR	NR	No response
Carrión Madroñal et al. (2019) <sup>16</sup>	Case report	NSCLC (pembrolizumab)	1	4	Yes	NR	Dose: 5 mg/kg No. infusions: 1	No response
Alzghoul et al. (2019) <sup>23</sup>	Case report	NSCLC (durvalumab)	1	4	Yes	NR	Dose: 500 mg No. infusions: 1	Clinical improvement
<b>Case series</b>								
Sun et al. (2025) <sup>29</sup>	Case series	Not specified	4	NR	Yes	NR	NR	No response
Tan et al. (2023) <sup>30</sup>	Case series	Not specified	3	NR	Yes	NR	NR	2 complete response 1 no response
Frost et al. (2023) <sup>31</sup>	Case series	Lung cancer ICI not specified	6	≥ 3	Yes	NR	NR	No response
Sheshadri et al. (2022) <sup>32</sup>	Case series	AML ICI not specified	2	NR	Yes	NR	NR	No response
AML: acute myeloid leukaemia; BD: twice daily; ICI: immune checkpoint inhibitor, IVIG: intravenous immunoglobulin, MMF: mycophenolate mofetil, No.: number; NR: not reported, NSCLC: non-small cell lung cancer								